Erkki I. Ruoslahti - Infectious Diseases

Author Information

Erkki I. Ruoslahti is a prominent researcher affiliated with the Cancer Research Center at the Sanford Burnham Prebys Medical Discovery Institute, located in La Jolla, CA, USA. His work primarily focuses on innovative approaches in cancer therapy and molecular medicine, particularly in the development and application of nanoparticle-based delivery systems for therapeutic agents.

Research Contributions

Erkki I. Ruoslahti has made significant contributions to the field of nanomedicine and targeted therapy. His research includes the development of nanoparticle systems for the delivery of therapeutic agents, such as siRNA and antisense oligonucleotides, to cancer cells, including glioblastoma and prostate cancer. Notably, his work on fusogenic porous silicon nanoparticles and peptide-guided nanoparticles demonstrates his commitment to improving the specificity and efficacy of cancer treatments. His research has also explored the use of synthetic protein nanoparticles for systemic brain tumor delivery and the enhancement of tumor penetration using iRGD-liposomes.

Aliases

Erkki I. Ruoslahti is known by several aliases, including Erkki Ruoslahti, E Ruoslahti, E. Ruoslahti, and E I Ruoslahti. These variations are often used interchangeably in academic and scientific publications.

Publication and Citation Metrics

Metric	Value
Citation Count	96,198
h-index	155
Paper Count	660

Publications:

Fusogenic porous silicon nanoparticles as a broad-spectrum immunotherapy against bacterial infections.

DOI: 10.1039/d0nh00624f

Year: 2021

iRGD-liposomes enhance tumor delivery and therapeutic efficacy of antisense oligonucleotide drugs against primary prostate cancer and bone metastasis

DOI: 10.1101/2021.01.08.426005

Year: 2021

Tumor-penetrating therapy for β5 integrin-rich pancreas cancer

DOI: 10.1038/s41467-021-21858-1

Year: 2021

Nutrient-Dependency of CendR Endocytosis Pathway is Uniquely Regulated by Mutant Kras and Targetable

DOI: 10.2139/ssrn.3858913

Year: 2021

iRGD‐Liposomes Enhance Tumor Delivery and Therapeutic Efficacy of Antisense Oligonucleotide Drugs against Primary Prostate Cancer and Bone Metastasis

DOI: 10.1002/adfm.202100478

Year: 2021

Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy

DOI: 10.1038/s41467-020-19225-7

Year: 2020

Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy

DOI: 10.1101/862581

Year: 2020

Silver Nanocarriers Targeted with a CendR Peptide Potentiate the Cytotoxic Activity of an Anticancer Drug

DOI: 10.1002/adtp.202000097

Year: 2020

Securing the Payload, Finding the Cell, and Avoiding the Endosome: Peptide‐Targeted, Fusogenic Porous Silicon Nanoparticles for Delivery of siRNA

DOI: 10.1002/adma.201902952

Year: 2019

Peptide-guided nanoparticles for glioblastoma targeting.

DOI: 10.1016/j.jconrel.2019.06.018

Year: 2019

Why is it Important in Infectious Diseases?

What are the future prospects of Dengvaxia?

What are the Challenges in Controlling Schistosomiasis?

How Can Avian Influenza be Prevented?

How Should Condoms Be Used Correctly?

Can E. Coli Infections Lead to Long-Term Complications?

How Are Fungal Infections Treated?

How Does Prevalence Differ from Incidence?

Are There Specific Hygiene Recommendations for Food Safety?

What Are the General Principles of Treatment?

Partnered Content Networks

Relevant Topics